Please visit the READ MORE link below to learn more about this initiative.
We are aware that the coronavirus (COVID-19) outbreak is putting sustained pressure on genomic testing services globally. EMQN has issued a statement on its impact on EQA timetables for 2020.
The EQA distributions planned for May and June 2020 have been postponed - please click the button below to see which schemes have been affected.
Manchester, UK, 6th March 2020: EMQN CIC today announced it is collaborating with GenQA to launch a pilot EQA scheme for HRR gene testing in patients with advanced Prostate Cancer.
Manchester, UK, 26th February 2020: EMQN CIC today announced it is collaborating with GenQA to launch an EQA Scheme for cfDNA testing for EGFR mutations in lung cancer.
We provide ISO 17043 accredited External Quality Assessment (EQA) or Proficiency Testing (PT) schemes which are designed to test the whole analytical process of a molecular diagnostics laboratory including the ability to interpret data in the light of clinical information supplied with a referral, and to produce a clear and accurate report.
Membership of EMQN gives your laboratory access to world class resources in genomics to help improve your performance.
The latest news and press releases
ISSAID/EMQN Best Practice Guidelines for SAIDs/HRF Published - https://t.co/OSOY7gkAwY
Please read our joint statement (click https://t.co/XdNbUErqDb) with GenQA on the pilot EQA scheme for NGS Somatic variant testing.
FINAL results of the 2019 BRCA Ovarian EQA scheme(s) published today. Please login to your EMQN account to view the… https://t.co/Fnx5ZXWT5P
The FINAL results from 2019 NIPT EQA scheme(s) have been published (see https://t.co/yZcchpR7Ro for more information).